Garry E Menzel - Net Worth and Insider Trading
Garry E Menzel Net Worth
The estimated net worth of Garry E Menzel is at least $721,483 dollars as of 2024-06-05. Garry E Menzel is the President and CEO of TCR2 Therapeutics Inc and owns about 436,268 shares of TCR2 Therapeutics Inc (TCRR) stock worth over $645,677. Garry E Menzel is also the Director of Adaptimmune Therapeutics PLC and owns about 75,056 shares of Adaptimmune Therapeutics PLC (ADAP) stock worth over $75,807. Details can be seen in Garry E Menzel's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Garry E Menzel has not made any transactions after 2023-07-10 and currently still holds the listed stock(s).
Transaction Summary of Garry E Menzel
Garry E Menzel Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Garry E Menzel owns 6 companies in total, including Black Diamond Therapeutics Inc (BDTX) , TCR2 Therapeutics Inc (TCRR) , and DaVita Inc (DVA) among others .
Click here to see the complete history of Garry E Menzel’s form 4 insider trades.
Insider Ownership Summary of Garry E Menzel
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
BDTX | Black Diamond Therapeutics Inc | 2020-01-29 | director |
TCRR | TCR2 Therapeutics Inc | 2022-12-13 | director & President & CEO |
DVA | DaVita Inc | 2013-09-09 | Senior Vice President & Finance |
2012-10-04 | COO & Executive VP & Finance | ||
2020-08-13 | director | ||
2023-07-10 | director |
Garry E Menzel Latest Holdings Summary
Garry E Menzel currently owns a total of 2 stocks. Among these stocks, Garry E Menzel owns 436,268 shares of TCR2 Therapeutics Inc (TCRR) as of December 13, 2022, with a value of $645,677 and a weighting of 89.49%. Garry E Menzel also owns 75,056 shares of Adaptimmune Therapeutics PLC (ADAP) as of July 10, 2023, with a value of $75,807 and a weighting of 10.51%.
Latest Holdings of Garry E Menzel
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
TCRR | TCR2 Therapeutics Inc | 2022-12-13 | 436,268 | 1.48 | 645,677 |
ADAP | Adaptimmune Therapeutics PLC | 2023-07-10 | 75,056 | 1.01 | 75,807 |
Holding Weightings of Garry E Menzel
Garry E Menzel Form 4 Trading Tracker
According to the SEC Form 4 filings, Garry E Menzel has made a total of 4 transactions in TCR2 Therapeutics Inc (TCRR) over the past 5 years, including 0 buys and 4 sells. The most-recent trade in TCR2 Therapeutics Inc is the sale of 31,938 shares on December 13, 2022, which brought Garry E Menzel around $35,132.
According to the SEC Form 4 filings, Garry E Menzel has made a total of 1 transactions in Adaptimmune Therapeutics PLC (ADAP) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Adaptimmune Therapeutics PLC is the sale of 47,702 shares on July 10, 2023, which brought Garry E Menzel around $43,409.
Insider Trading History of Garry E Menzel
- 1
Garry E Menzel Trading Performance
Garry E Menzel Ownership Network
Ownership Network List of Garry E Menzel
Ownership Network Relation of Garry E Menzel
Garry E Menzel Owned Company Details
What does Black Diamond Therapeutics Inc do?
Who are the key executives at Black Diamond Therapeutics Inc?
Garry E Menzel is the director of Black Diamond Therapeutics Inc. Other key executives at Black Diamond Therapeutics Inc include 10 percent owner Biotech Growth N V , director & 10 percent owner Ali Behbahani , and director & See Remarks David M. Epstein .
Black Diamond Therapeutics Inc (BDTX) Insider Trades Summary
Over the past 18 months, Garry E Menzel made no insider transaction in Black Diamond Therapeutics Inc (BDTX). Other recent insider transactions involving Black Diamond Therapeutics Inc (BDTX) include a net purchase of 3,140,000 shares made by Biotech Growth N V , a net purchase of 1,000,000 shares made by Ali Behbahani , and a net purchase of 935,850 shares made by Ra Capital Healthcare Fund Lp .
In summary, during the past 3 months, insiders sold 0 shares of Black Diamond Therapeutics Inc (BDTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 25,000 shares of Black Diamond Therapeutics Inc (BDTX) were sold and 5,132,213 shares were bought by its insiders, resulting in a net purchase of 5,107,213 shares.
Black Diamond Therapeutics Inc (BDTX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Black Diamond Therapeutics Inc Insider Transactions
Garry E Menzel Mailing Address
Above is the net worth, insider trading, and ownership report for Garry E Menzel. You might contact Garry E Menzel via mailing address: C/o Regulus Therapeutics Inc., 3545 John Hopkins Court Suite 210, San Diego Ca 92121.